Abbott and Celera form molecular diagnostics alliance
This article was originally published in Clinica
Abbott Laboratories and Celera Diagnostics are forming an alliance aimed at strengthening their positions in the fast-growing $1bn molecular diagnostic market. The collaboration will focus on the development, manufacture and marketing of a broad range of in vitro molecular diagnostic products, for disease detection, disease progression monitoring and choice of selection.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.